Skip to main content
Year archive

Sanofi — 2022 filings

All 253 regulatory filings released by Sanofi (SAN) in 2022, sourced directly from the official regulator.

253 Filings
2022 Period
2022 filings (253)
Filing Released Lang
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2022-12-27 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2022-12-27 English
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Earnings Release FY 2022
2022-12-21 English
Communiqué de presse: Dupixent® (dupilumab) : publication de résultats positifs de phase III chez l’adulte et l’adolescent atteints d’œsophagite à éosinophiles dans le New England Journal of Medicine
Regulatory Filings
2022-12-21 French
6-K
Foreign Filer Report
2022-12-20 English
Communiqué de presse: Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie
Capital/Financing Update
2022-12-19 French
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
Regulatory Filings
2022-12-19 English
Sanofi: Information concerning the total number of voting rights and shares November 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-19 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions Novembre 2022
Share Issue/Capital Change
2022-12-19 French
Communiqué de presse: Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’UE pour le traitement de l’œsophagite à éosinophiles
Regulatory Filings
2022-12-16 French
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
Regulatory Filings
2022-12-16 English
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
Regulatory Filings
2022-12-15 English
Communiqué de presse: Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement du prurigo nodulaire
Regulatory Filings
2022-12-15 French
Communiqué de presse : Annonce de Sanofi au sujet de Horizon Therapeutics plc (“Horizon”)
M&A Activity
2022-12-11 French
Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)
M&A Activity
2022-12-11 English
6-K
Foreign Filer Report
2022-12-02 English
Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules
M&A Activity
2022-12-02 English
Communiqué de presse : Annonce de Sanofi au sujet de la règle 2.12 des "takeover rules"
M&A Activity
2022-12-02 French
Communiqué de presse : Acoziborole : un médicament expérimental oral et à dose unique pourrait permettre d’éliminer la maladie du sommeil en Afrique
Regulatory Filings
2022-11-30 French
Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa
Earnings Release FY 2022
2022-11-30 English
6-K
Foreign Filer Report
2022-11-21 English
Communiqué de presse: La Commission européenne approuve Enjaymo® (sutimlimab) pour le traitement de l’anémie hémolytique de l’adulte atteint de la maladie des agglutinines froides
Regulatory Filings
2022-11-17 French
Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
Regulatory Filings
2022-11-17 English
6-K
Foreign Filer Report
2022-11-15 English
Sanofi: Information concerning the total number of voting rights and shares – October 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-14 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-14 French
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
Regulatory Filings
2022-11-11 English
Communiqué de presse: Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’Union européenne pour le traitement du prurigo nodulaire
Regulatory Filings
2022-11-11 French
6-K
Foreign Filer Report
2022-11-10 English
Communiqué de presse : VidPrevtyn® Beta, le vaccin de rappel nouvelle génération contre la COVID-19 de Sanofi et GSK, approuvé par la Commission européenne
Regulatory Filings
2022-11-10 French
Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
Regulatory Filings
2022-11-10 English
Communiqué de presse: La Commission européenne accorde la première autorisation au monde à Beyfortus® (nirsevimab) pour la prévention des infections par le VRS chez le nourisson
Regulatory Filings
2022-11-04 French
Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
Regulatory Filings
2022-11-04 English
6-K
Foreign Filer Report
2022-10-28 English
Press Release: Continued strong growth in Q3 with key regulatory milestones achieved
Earnings Release Q3 2022
2022-10-28 English
Communiqué de Presse : Forte performance au T3 et avancées règlementaires clés
Earnings Release Q3 2022
2022-10-28 French
Franchissement de seuil
Major Shareholding Notification
2022-10-18 French
6-K
Foreign Filer Report
2022-10-17 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septembre 2022
Share Issue/Capital Change
2022-10-13 French
Sanofi: Information concerning the total number of voting rights and shares - September 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-13 English
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
Earnings Release Q4 2022
2022-10-11 English
6-K
Foreign Filer Report
2022-10-03 English
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Regulatory Filings
2022-09-29 English
Communiqué de presse: Dupixent® (dupilumab), premier et seul médicament approuvé par la FDA pour le traitement du prurigo nodulaire
Regulatory Filings
2022-09-29 French
Communiqué de presse : Mise en ligne du document «Q3 2022 Memorandum for modelling purposes»
Report Publication Announcement
2022-09-28 French
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
Report Publication Announcement
2022-09-28 English
6-K
Foreign Filer Report
2022-09-22 English
Communiqué de presse: Le CHMP recommande l’approbation de Beyfortus® (nirsevimab) pour la prévention des infections par le VRS chez le nourrisson
Regulatory Filings
2022-09-16 French
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
Regulatory Filings
2022-09-16 English
Sanofi: Information concerning the total number of voting rights and shares - August 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-13 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-13 English
6-K
Foreign Filer Report
2022-09-12 English
Communiqué de presse: Des données de phase III de dernière heure présentées au Congrès de l’EADV 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo n
Regulatory Filings
2022-09-08 French
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Regulatory Filings
2022-09-08 English
Des données de dernière minute sur Dupixent® (dupilumab) présentées au congrès de l’ERS 2022 montrent un profil de sécurité et d’efficacité homogène pendant une durée pouvant atteindre deux ans, chez
Regulatory Filings
2022-09-05 French
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Regulatory Filings
2022-09-05 English
Communiqué de presse: Evolution au sein du Conseil d’Administration
Board/Management Information
2022-09-05 French
Press Release: Evolution of the Board of Directors
Board/Management Information
2022-09-05 English
6-K
Foreign Filer Report
2022-09-02 English
Communiqué de presse: XenpozymeTM (olipudase alfa-rpcp) approuvé par la FDA – premier médicament indiqué expressément pour le traitement des manifestations non neurologiques du déficit en sphingomyéli
Earnings Release Q3 2022
2022-08-31 French
Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
Regulatory Filings
2022-08-31 English
Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A
Regulatory Filings
2022-08-30 English
Communiqué de presse: La FDA accorde un examen prioritaire à l’efanesoctocog alpha pour le traitement de l’hémophilie A
Regulatory Filings
2022-08-30 French
6-K
Foreign Filer Report
2022-08-17 English
Press Release: Sanofi provides update on amcenestrant clinical development program
Legal Proceedings Report
2022-08-17 English
Communiqué de presse: Sanofi fait le point sur le programme de développement clinique de l’amcenestrant
Legal Proceedings Report
2022-08-17 French
6-K
Foreign Filer Report
2022-08-11 English
6-K
Foreign Filer Report
2022-08-08 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juillet 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-08 French
Sanofi: Information concerning the total number of voting rights and shares – July 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-08 English
Communiqué de presse : Sanofi et Innovent Biologics nouent une collaboration stratégique pour intensifier le développement de médicaments en oncologie et étendre leur présence en Chine
Regulatory Filings
2022-08-04 French
Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
Capital/Financing Update
2022-08-04 English
6-K
Foreign Filer Report
2022-07-28 English
Communiqué de presse : Mise en ligne du rapport financier semestriel 2022 de Sanofi
Report Publication Announcement
2022-07-28 French
Press Release: Online availability of Sanofi’s half-year financial report for 2022
Report Publication Announcement
2022-07-28 English
Rapport financier semestriel 2022 de Sanofi
Interim / Quarterly Report H1 2022
2022-07-28 French
Sanofi’s half-year financial report for 2022
Interim / Quarterly Report H1 2022
2022-07-28 English
6-K
Foreign Filer Report
2022-07-28 English
Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
Earnings Release Q2 2022
2022-07-28 English
Communiqué de presse : Forte performance au T2 : hausse des perspectives 2022 et nombreuses avancées R&D en immunologie et maladies rares
Earnings Release Q2 2022
2022-07-28 French
Sanofi: Informations relatives au nombre de droits de vote et d'actions – JUIN 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-20 French
Sanofi: Information concerning the total number of voting rights and shares – June 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-20 English
6-K
Foreign Filer Report
2022-07-20 English
Communiqué de presse: Résultats positifs de phase III pour Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 1 à 11 ans
Regulatory Filings
2022-07-14 French
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Earnings Release Q3 2022
2022-07-14 English
6-K
Foreign Filer Report
2022-07-13 English
Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
Earnings Release FY 2021
2022-07-10 English
Des données pivots démontrent que l’efanesoctogog alpha une fois par semaine confère une protection supérieure contre les saignements, comparativement à une prophylaxie antérieure par facteur de rempl
Regulatory Filings
2022-07-10 French
6-K
Foreign Filer Report
2022-07-08 English
Sanofi Global Health lance la marque Impact® à but non lucratif pour 30 médicaments destinés aux pays à faible revenu
Regulatory Filings
2022-07-04 French
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
Regulatory Filings
2022-07-04 English
6-K
Foreign Filer Report
2022-06-30 English
FORM 11-K
Regulatory Filings
2022-06-29 English
FORM 11-K
Regulatory Filings
2022-06-29 English
6-K
Foreign Filer Report
2022-06-28 English
Communiqué de presse: Nexviadyme® (avalglucosidase alpha), nouveau traitement de référence potentiel de la maladie de Pompe, a été approuvé par la Commission européenne
Regulatory Filings
2022-06-28 French
Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
Regulatory Filings
2022-06-28 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – MAI 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-27 French
Sanofi: Information concerning the total number of voting rights and shares – May 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-27 English
Mise en ligne du document «Q2 2022 Memorandum for modelling purposes»
Earnings Release Q2 2022
2022-06-24 French
Availability of the Q2 2022 Memorandum for modelling purposes
Report Publication Announcement
2022-06-24 English
Communiqué de presse : Vaccin COVID-19 Bêta de Sanofi-GSK : succès de la première étude d’efficacité contre Omicron
Earnings Release FY 2022
2022-06-24 French
Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
Earnings Release FY 2022
2022-06-24 English
Franchissement de seuil
Major Shareholding Notification
2022-06-23 French
6-K
Foreign Filer Report
2022-06-16 English
6-K
Foreign Filer Report
2022-06-13 English
Communiqué de presse: Le vaccin de rappel COVID-19 de Sanofi-GSK induit une forte réponse immunitaire contre les variants préoccupants, dont Omicron
Earnings Release FY 2022
2022-06-13 French
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Regulatory Filings
2022-06-13 English
Sanofi lance son premier Accélérateur digital porté par de nouveaux talents et centré sur la croissance
Regulatory Filings
2022-06-08 French
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
Board/Management Information
2022-06-08 English
Communiqué de presse: La FDA approuve Dupixent® (dupilumab) – premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 mois à 5 ans
Regulatory Filings
2022-06-07 French
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Regulatory Filings
2022-06-07 English
6-K
Foreign Filer Report
2022-06-07 English
Sanofi lance son plan mondial 2022 d’actionnariat salarié ouvert à 86 000 salariés
Remuneration Information
2022-06-07 French
Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
Share Issue/Capital Change
2022-06-07 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Avril 2022
Share Issue/Capital Change
2022-06-02 French
Sanofi: Information concerning the total number of voting rights and shares – April 2022
Regulatory Filings
2022-06-02 English
Communiqué de presse: Sanofi accorde à Regeneron les droits de licence exclusifs sur Libtayo® (cemiplimab) à l’échelle mondiale
Regulatory Filings
2022-06-02 French
Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)
Regulatory Filings
2022-06-02 English
Communiqué de presse: La FDA accorde la désignation de « Traitement innovant » à l’efanesoctocog alpha pour le traitement de l’hémophilie A
Regulatory Filings
2022-06-01 French
Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
Regulatory Filings
2022-06-01 English
6-K
Foreign Filer Report
2022-05-31 English
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
Regulatory Filings
2022-05-31 English
6-K
Foreign Filer Report
2022-05-25 English
SD
Regulatory Filings
2022-05-25 English
Communiqué de presse: La FDA approuve Dupixent® (dupilumab) – premier médicament pour le traitement de l’œsophagite à éosinophiles de l’adulte et de l’enfant à partir de 12 ans
Regulatory Filings
2022-05-20 French
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
Regulatory Filings
2022-05-20 English
S-8
Registration Form
2022-05-18 English
6-K
Foreign Filer Report
2022-05-17 English
S-8 POS
Regulatory Filings
2022-05-17 English
6-K
Foreign Filer Report
2022-05-16 English
Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
Earnings Release FY 2022
2022-05-15 English
Communiqué de presse: De nouvelles analyses des données relatives au nirsevimab confortent son efficacité contre le VRS
Regulatory Filings
2022-05-11 French
Press Release: New nirsevimab data analyses reinforce efficacy against RSV
Regulatory Filings
2022-05-11 English
6-K
Foreign Filer Report
2022-05-09 English
Press Release: Foundation S: Sanofi’s new philanthropic spearhead
Regulatory Filings
2022-05-04 English
Communiqué de presse : Foundation S, nouveau fer de lance du mécénat de Sanofi
Environmental & Social Information
2022-05-04 French
Communiqué de presse : Assemblée Générale Annuelle du 3 mai 2022
AGM Information
2022-05-03 French
Press Release: Annual General Meeting of May 3, 2022
AGM Information
2022-05-03 English
6-K
Foreign Filer Report
2022-04-29 English
6-K
Foreign Filer Report
2022-04-28 English
Communiqué de presse : Poursuite de la forte hausse du BNPA des activités portée par la croissance des ventes et des marges au T1
Earnings Release Q1 2022
2022-04-28 French
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
Earnings Release Q1 2022
2022-04-28 English
Sanofi: Information concerning the total number of voting rights and shares – March 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-26 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – MARS 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-26 French
Communiqué de presse : Sanofi s’associe à McLaren Racing pour accélérer l’excellence de son outil industriel
Regulatory Filings
2022-04-26 French
Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence
Regulatory Filings
2022-04-26 English
6-K
Foreign Filer Report
2022-04-19 English
Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
Earnings Release FY 2022
2022-04-14 English
Communiqué de presse: Publication, dans le New England Journal of Medicine, des résultats positifs de phase I/II du rilzabrutinib dans le traitement de la thrombocytopénie immune
Regulatory Filings
2022-04-14 French
Sanofi - AGM 03.05.2022 - Mise à disposition des documents préparatoires
AGM Information
2022-04-12 French
Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents
AGM Information
2022-04-12 English
6-K
Foreign Filer Report
2022-04-07 English
Communiqué de presse: La Commission européenne approuve Dupixent® (dupilumab) pour le traitement des enfants âgés de 6 à 11 ans présentant un asthme sévère avec signature inflammatoire de type 2
Regulatory Filings
2022-04-07 French
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Regulatory Filings
2022-04-07 English
6-K
Foreign Filer Report
2022-04-04 English
Communiqué de presse : Sanofi crée un Conseil Diversité, Équité et Inclusion, une première dans l’industrie pharmaceutique
Governance Information
2022-04-04 French
Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
Board/Management Information
2022-04-04 English
Communiqué de presse: La FDA accepte d’accorder un examen prioritaire à Dupixent® (dupilumab) pour le traitement des patients de 12 ans et plus souffrant d’œsophagite à éosinophiles
Regulatory Filings
2022-04-04 French
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Regulatory Filings
2022-04-04 English
6-K
Foreign Filer Report
2022-04-01 English
Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
Share Issue/Capital Change
2022-04-01 English
Communiqué de presse : Cotation d’EUROAPI sur Euronext Paris prévue le 6 mai 2022
Capital/Financing Update
2022-04-01 French
6-K
Foreign Filer Report
2022-03-31 English
Communiqué de presse : Sanofi lance avec succès une émission obligataire indexée sur l’accès aux médicaments
Capital/Financing Update
2022-03-31 French
Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
Capital/Financing Update
2022-03-31 English
6-K
Foreign Filer Report
2022-03-30 English
Communiqué de presse : Mise en ligne du document «Q1 2022 Memorandum for modelling purposes»
Report Publication Announcement
2022-03-30 French
Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
Report Publication Announcement
2022-03-30 English
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
M&A Activity
2022-03-29 English
Communiqué de presse: Sanofi et IGM Biosciences annoncent un accord de collaboration en vue du développement de cibles en oncologie, immunologie et inflammation
Regulatory Filings
2022-03-29 French
Communiqué de presse: Sanofi poursuit sa trajectoire de leadership en immunologie avec Dupixent® (dupilumab) comme levier de croissance
Earnings Release FY 2022
2022-03-29 French
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
Earnings Release FY 2022
2022-03-29 English
Communiqué de presse : Approbation de Xenpozyme® (olipudase alpha) au Japon – premier et seul médicament approuvé pour le traitement du déficit en sphingomyélinase acide
Regulatory Filings
2022-03-28 French
Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
Earnings Release FY 2022
2022-03-28 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – FEVRIER 2022
Share Issue/Capital Change
2022-03-26 French
Sanofi: Information concerning the total number of voting rights and shares – February 2022
Declaration of Voting Results & Voting Rights Announcements
2022-03-26 English
Communiqué de presse: Des données de phase III de dernière minute présentées au Congrès 2022 de l’AAD montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo n
Regulatory Filings
2022-03-26 French
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Regulatory Filings
2022-03-26 English
6-K
Foreign Filer Report
2022-03-22 English
Communiqué de presse : Sanofi lance le projet de cotation d'EUROAPI sur Euronext Paris
Share Issue/Capital Change
2022-03-18 French
Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
Share Issue/Capital Change
2022-03-18 English
Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
Regulatory Filings
2022-03-16 English
Communiqué de presse : Sanofi et Seagen annoncent leur collaboration pour le développement et la commercialisation de plusieurs nouveaux conjugués anticorps-médicament
Regulatory Filings
2022-03-16 French
6-K
Foreign Filer Report
2022-03-15 English
Sanofi annonce une collaboration de 300 millions d’euros avec Blackstone Life Sciences pour faire avancer le développement d’un médicament innovant contre le myélome multiple
Regulatory Filings
2022-03-15 French
Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma
Regulatory Filings
2022-03-15 English
Sanofi fait le point sur l’étude de phase II évaluant l’amcenestrant dans le traitement du cancer du sein ER+/HER2- au stade avancé ou métastatique
Legal Proceedings Report
2022-03-14 French
Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer
Earnings Release Q1 2022
2022-03-14 English
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Earnings Release FY 2022
2022-03-09 English
Étude pivot efanesoctocog alpha: critère d’évaluation primaire et principaux critères secondaires atteints dans le traitement de l’hémophilie A ; supériorité illustrée sur une prophylaxie antérieure p
Earnings Release FY 2022
2022-03-09 French
Sanofi reconnue par S&P parmi les entreprises les plus engagées en faveur du développement durable
Environmental & Social Information
2022-03-08 French
Sanofi recognized by S&P as one of the most sustainability-committed companies
Environmental & Social Information
2022-03-08 English
6-K
Foreign Filer Report
2022-03-04 English
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Earnings Release FY 2022
2022-03-03 English
Le nirsevimab protège significativement les nourrissons contre les infections à VRS selon un essai de phase III
Investor Presentation
2022-03-03 French
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Earnings Release FY 2022
2022-02-26 English
Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes de l’œsophagite à éosinop
Earnings Release FY 2022
2022-02-26 French
Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) diminue significativement les démangeaisons et l’urticaire des patients souf
Earnings Release FY 2022
2022-02-26 French
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Earnings Release FY 2022
2022-02-26 English
6-K
Foreign Filer Report
2022-02-24 English
Dépôt du Document d’Enregistrement Universel 2021, contenant le Rapport Financier Annuel, et du « Form 20-F » américain
Report Publication Announcement
2022-02-23 French
Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Report Publication Announcement FY 2021
2022-02-23 English
IRANNOTICE
Regulatory Filings
2022-02-23 English
Document d'Enregistrement Universel 2021
Annual Report (ESEF) FY 2021
2022-02-23 French
Document d'Enregistrement Universel 2021
Annual Report (ESEF) FY 2021
2022-02-23 French
20-F
Annual Report FY 2021
2022-02-23 English
Sanofi et GSK vont demander l’approbation réglementaire de leur vaccin contre la COVID-19
Regulatory Filings
2022-02-23 French
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Regulatory Filings
2022-02-23 English
Annual Report 2021 Form 20F
Annual Report FY 2021
2022-02-23 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - JANVIER 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-22 French
Sanofi: Information concerning the total number of voting rights and shares - January 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-22 English
Le Conseil d’administration de Sanofi propose la nomination de Carole Ferrand, Emile Voest et Antoine Yver en qualité d’administrateurs indépendants
Board/Management Information
2022-02-22 French
Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
Board/Management Information
2022-02-22 English
SCHEDULE 13G
Major Shareholding Notification
2022-02-22 English
Point d’actualité sur le programme de phase III relatif à Dupixent® (dupilumab) dans le traitement de l’urticaire chronique spontanée
Regulatory Filings
2022-02-18 French
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Earnings Release FY 2022
2022-02-18 English
SCHEDULE 13G
Major Shareholding Notification
2022-02-15 English
6-K
Foreign Filer Report
2022-02-14 English
SC 13G
Major Shareholding Notification
2022-02-14 English
La FDA accepte d’accorder un examen prioritaire à Dupixent® (dupilumab) pour le traitement de la dermatite atopique modérée à sévère de l’enfant de 6 mois à 5 ans
Regulatory Filings
2022-02-10 French
FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Regulatory Filings
2022-02-10 English
L’olipudase alpha permet d’obtenir des améliorations soutenues de plusieurs manifestations cliniques du déficit en sphingomyélinase acide
Earnings Release FY 2022
2022-02-09 French
Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD
Regulatory Filings
2022-02-09 English
SC 13G
Major Shareholding Notification
2022-02-08 English
La FDA approuve Enjaymo™ (sutimlimab-jome), le premier traitement pour les patients atteints de la maladie des agglutinines froides
Earnings Release Q1 2022
2022-02-04 French
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
Regulatory Filings
2022-02-04 English
6-K
Foreign Filer Report
2022-02-04 English
6-K
Foreign Filer Report
2022-02-04 English
Communiqué de presse | 2021 : forte croissance du chiffre d’affaires et du BNPA des activités permettant d’augmenter l’investissement en R&D
Earnings Release Q4 2021
2022-02-04 French
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
Earnings Release Q4 2021
2022-02-04 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-03 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2022-02-01 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2022-02-01 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2022-01-31 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2022-01-31 English
Le CHMP recommande l’approbation de Dupixent® (dupilumab) pour le traitement de l’asthme sévère associé à une inflammation de type 2 chez l’enfant âgé de 6 à 11 ans
Regulatory Filings
2022-01-31 French
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
Regulatory Filings
2022-01-31 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2022-01-26 English
6-K
Foreign Filer Report
2022-01-24 English
Deuxième essai de phase III positif pour Dupixent® (dupilumab) dans le traitement du prurigo nodulaire, avec des améliorations significatives pour les patients
Regulatory Filings
2022-01-19 French
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Regulatory Filings
2022-01-19 English
Sanofi: Information concerning the total number of voting rights and shares – December 2021
Declaration of Voting Results & Voting Rights Announcements
2022-01-17 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Décembre 2021
Share Issue/Capital Change
2022-01-17 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2022-01-14 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2022-01-14 French
6-K
Foreign Filer Report
2022-01-12 English
Exscientia et Sanofi établissent une collaboration de recherche stratégique pour développer un portefeuille de médicaments de précision conçus grâce à l’intelligence artificielle
Regulatory Filings
2022-01-07 French
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Capital/Financing Update
2022-01-07 English
Availability of the Q4 2021 Memorandum for modelling purposes
Report Publication Announcement
2022-01-04 English
Mise en ligne du document «Q4 2021 Memorandum for modelling purposes»
Report Publication Announcement
2022-01-04 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2022-01-03 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2022-01-03 French